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Abstract
Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes
mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-
glucosidase inhibitors. Novel compounds are represented by the incretin mimetic drugs like glucagon like
peptide-1 (GLP-1), the dipeptidyl peptidase 4 (DPP-4) inhibitors, dual peroxisome proliferator-activated
receptors (PPAR) agonists (glitazars) and amylin mimetic drugs. We review the cardiovascular effects of
these drugs in an attempt to improve knowledge regarding their potential risks when treating T2DM in
cardiac patients. Metformin may lead to lethal lactic acidosis, especially in patients with clinical conditions
that predispose to this complication, such as recent myocardial infarction, heart or renal failure.
Sulfonylureas exert their effect by closing the ATP-dependent potassium channels. This prevents the
opening of these channels during myocardial ischemia, impeding the necessary hyperpolarization that
protects the cell. The combined sulfonylurea/metformin therapy reveals additive effects on mortality in
patients with coronary artery disease (CAD). Meglitinides effects are similar to those of sulfonylureas, due
to their almost analogous mechanism of action. Glitazones lower leptin levels, leading to weight gain and
are unsafe in NYHA class III or IV. The long-term effects of alpha-glucosidase inhibitors on morbidity and
mortality rates is yet unknown. The incretin GLP-1 is associated with reductions in body weight and
appears to present positive inotropic effects. DPP-4 inhibitors influences on the cardiovascular system
seem to be neutral and patients do not gain weight. The future of glitazars is presently uncertain following
concerns about their safety. The amylin mimetic drug paramlintide, while a satisfactory adjuvant
medication in insulin-dependent diabetes, is unlikely to play a major role in the management of T2DM.
Summarizing the present information it can be stated that 1. Four out the five classical oral antidiabetic
drug groups present proven or potential cardiac hazards; 2. These hazards are not mere 'side effects', but
biochemical phenomena which are deeply rooted in the drugs' mechanism of action; 3. Current data
indicate that the combined glibenclamide/metformin therapy seems to present special risk and should be
avoided in the long-term management of T2DM with proven CAD; 4. Glitazones should be avoided in
patients with overt heart failure; 5, The novel incretin mimetic drugs and DPP-4 inhibitors – while usually
inadequate as monotherapy – appear to be satisfactory adjuvant drugs due to the lack of known
undesirable cardiovascular effects; 6. Customized antihyperglycemic pharmacological approaches should
be implemented for the achievement of optimal treatment of T2DM patients with heart disease. In this
context, it should be carefully taken into consideration whether the leading clinical status is CAD or heart
failure.
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Introduction
Diabetes mellitus threatens to become a global health cri-
sis; treating diabetes and its complications is going to
dominate future health care expenditures. Type 2 diabetes
mellitus (T2DM) accounts for about 90% of the total dia-
betic population, and coronary artery disease (CAD) is the
most common cause of morbidity and mortality. Cardio-
vascular deaths are increased up to fourfold in diabetics
compared with their nondiabetic counterparts [1]. More
than two-thirds of people with diabetes are obese. They
require drugs that stimulate beta-cells to make more insu-
lin and/or drugs that help insulin work better. When these
do not work any longer, people require insulin. Unfortu-
nately this form of diabetes is growing at an alarming rate.
Since these patients will receive antidiabetic therapy
indefinitely, any undesirable cardiovascular effects from
well-known and widely used oral antidiabetic drugs
should be analyzed in depth. In patients with T2DM, the
University Group Diabetes Program (UGDP) reported in
1970 a higher frequency of major cardiovascular events in
patients treated with tolbutamide, a sulfonylurea [2].
Awareness of this issue has increased during recent years
following the detection of harmful influences of sulfony-
lureas on the ischemic myocardial cell [3,4]. On the other
hand, cardiovascular derangement associated with the use
of metformin has also been reported during both short
[5,6] and long-term follow-up [7].
When oral antidiabetic monotherapy does not achieve the
glycemic goal, combination treatment is implemented. A
sulfonylurea – usually glibenclamide (known also as gly-
buride in the USA) – plus metformin constitute the most
widely used antihyperglycemic combination in clinical
practice [8]. However, the safety of this therapeutic regi-
men in long-term treatment is questionable [9]. The use
of insulin in T2DM is also controversial. Nonetheless,
after some years of disease oral therapy will be not yet
effective and the majority of patients will receive insulin
[10]. The issue whether the adverse cardiovascular effects
of several medications may be additive and detrimental
for the cardiac patients is of paramount importance and
has not yet been specifically addressed in problem-ori-
ented studies.
Insulin resistance represents the background of a series of
common factors for the development of both diabetes
and heart disease. These factors include genetics, hyper-
tension, obesity, hyperglycemia, dyslipidemia, prothrom-
botic state, aging, physical inactivity. Once both diseases
are clinically established, antidiabetic therapy per se may
lead to a further derangement of cardiovascular status.
Five types of classical oral antihperglycemic drugs are cur-
rently approved for the treatment of diabetes: biguanides,
sulfonylureas, meglitinides, glitazones and alpha-glucosi-
dase inhibitors. The novel antihyperglycemic compounds
are represented by the incretin mimetic drugs, the dipep-
tidyl peptidase (DPP-4) inhibitors, the dual peroxisome
proliferator-activated receptors (PPAR) agonists (glita-
zars) and the amylin mimetic drugs.
We will briefly review the cardiovascular effects of the
most commonly used antidiabetic drugs within these
types, in an attempt to improve knowledge and awareness
regarding their influences and potential risks when treat-
ing cardiac patients.
Classical medications
Biguanides
The biguanides were launched in the 1950's, and met-
formin is the only drug belonging to this class currently
available in most parts of the world. It reduces blood glu-
cose levels through suppression of gluconeogenesis, stim-
ulation of peripheral glucose uptake by tissue (mainly
skeletal muscles) in the presence of insulin, and decreased
absorption of glucose from the gastrointestinal tract. It
has no direct effects on beta-cells, does not produce
hypoglycemia, reduces glycohemoglobin (HgA1c) and
improves both blood lipid profile and fibrinolytic activity.
In contrast to other antidiabetic medications, metformin
does not cause weight gain and appears to be the drug of
choice in obese patients.
Despite these beneficial effects, metformin presents
potential disadvantages that may influence the cardiovas-
cular system. Gastrointestinal disturbances such as
diarrhea are frequent, and the intestinal absorption of
group B vitamins and folate is impaired during chronic
therapy [11]. This deficiency may lead to increased plasma
homocysteine levels which, in turn, accelerate the progres-
sion of vascular disease due to adverse effects on platelets,
clotting factors, and endothelium. The existence of a
graded association between homocysteine levels and
overall mortality in patients with CAD is well established
[12]. In addition, metformin may lead to lethal lactic aci-
dosis, especially in patients with clinical conditions that
predispose to this complication, such as heart failure or
recent myocardial infarction [6]. It should be remembered
that other drugs of the biguanide group – phenformin and
buformin – were withdrawn in many countries during the
1970's due to its link with lactic acidosis. A possible asso-
ciation of phenformin with increased cardiovascular mor-
tality has also been suggested [13]. Finally, metformin
undergoes renal excretion, presenting undesirable phar-
macologic interactions with several widely used cardio-
vascular drugs. The coadministration of nifedipine or
furosemide leads to increased metformin plasma levels.
Furthermore, digoxin, quinidine, and triamterene – which
are eliminated by renal tubular secretion – may interact
with metformin by competing for proximal renal tubular
transport systems [14]. Metformin was introduced in theCardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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USA in 1995, and serious controversies regarding cardio-
vascular safety followed its approval for use [5]. We have
found increased mortality in CAD patients receiving met-
formin after a 5-year follow-up [7]. However, it should be
stressed that this finding ought be treated with caution
since it arose from a nonrandomized study in which infor-
mation on drug doses and severity and duration of diabe-
tes was incomplete. Moreover, in further studies
metformin therapy was found to be associated with a
favorable cardiac outcome. Compared to sulfonylureas,
lesser morbidity in patients with heart failure [15] and
lesser cardiovascular hospitalization and mortality were
reported [16].
Sulfonylureas
These compounds are available nearly half a century.
Today, sulfonylureas continue to represent a mainstay of
therapy in patients with T2DM; their hypoglycemic
potency is directly related to baseline plasma glucose val-
ues [17]. At the cellular level, they exert their action by
closing the ATP-dependent potassium channels; this fea-
ture is responsible for both the insulinotropic effect and
the adverse effects on the heart [3,4]. Namely, sulfonylu-
reas bind with high affinity to a subunit of these channels
leading to depolarization of the cell. Under physiologic
conditions, the channels remain closed. During ischemia,
sulfonylureas may prevent their opening, avoiding the
necessary hyperpolarization that protects the cell by
impeding calcium influx [4]. In this context, it should be
stressed that cardiac and vascular sulfonylurea receptors
are structurally different from their pancreatic analog [4].
In fact, sulfonylureas have been reported to reduce resting
myocardial blood flow [18] to impair the recovery of con-
tractile function after experimental ischemia [19], to
increase the ultimate infarct size [20], to elicit proarrhyth-
mic effects [21], to abolish ischemic preconditioning in
animal models [22], and to increase early mortality in
patients with diabetes mellitus after direct angioplasty for
acute myocardial infarction [23]. Deterrence of myocar-
dial preconditioning by glibenclamide has also been dem-
onstrated in clinical trials [24].
It is important to stress that not all the undesirable effects
on cardiovascular outcome reported by the UGDP for the
first-generation sulfonylureas such as tolbutamide [2] can
be automatically extrapolated to the more modern sec-
ond-generation compounds such as glibenclamide or gli-
plizde [3]. In our experience, cardiovascular mortality
rates in CAD patients on sulfonylureas (mainly glibencla-
mide) were lower than those on combined sulfonylurea-
metformin therapy, and similar to the rates in patients on
diet alone [7]. Another relatively new sulfonylurea,
glimepiride, is more pancreas-specific and does not show
interaction with cardiovascular ATP-dependent potas-
sium channels [3,17,24].
Megltinides
Meglitinides are insulin secretagogues. The first drug of
this group, repaglinide, a benzoic acid derivative, was
introduced in the USA in 1998. The second, nateglinide,
is a d-phenylalanine derivative. Like sulfonylureas, these
compounds act by closing the ATP-dependent potassium
channels. However, its mechanism of action seem to be
more complex since possibly three meglitinide receptor
binding sites have been found on the beta-cells [25].
Despite a common basic mechanism of action, the insuli-
notropic effects of the two approved agents can be differ-
ently influenced by ambient glucose, leading to dissimilar
responsiveness. Nateglinide may exert a more physiologic
effect on insulin secretion – i.e. a glycemia-dependent
response – than repaglinide, presenting less propensity to
elicit hypoglycemia in vivo [26]. On the other hand, nate-
glinide presents a relatively lesser influence on HgA1c lev-
els. When used as monotherapy, these drugs reduce both
fasting plasma glucose and HgA1c, and have no signifi-
cant effects on lipid profile. They present some specific
characteristics that differentiate them from sulfonylureas:
pills are taken before meals (the medication should not be
administered if a meal is skipped), exhibit a short onset of
action and a short pharmacologic half life, and act mainly
on postprandial glucose.
The cardiovascular safety of these insulin secretagogues is
still uncertain. Increased morbidity, particularly acute
ischemic events, was observed for repaglinide after 1 year
compared with glibenclamide. Nevertheless, patients on
repaglinide appeared to have had more severe CAD at
baseline than those in the glibenclamide group, and when
adjustments were made the relative risk declined [27].
Thus, while definite assertions regarding cardiovascular
safety cannot be made at this stage, caution should be
implemented in view of the strong involvement of the
ATP-dependent potassium channels in the mechanism of
action.
Regarding nateglinide, it appears to have less affinity for
the potassium channels than repaglinide [28] and it is
interesting to mention a double effect: its action as a pran-
dial insulin-releasing agent may partly rely on inhibition
of GLP-1 degradation as well as beta-cell ATP-dependent
potassium channels inhibition [29].
Glitazones
This group of drugs, called also thiazolidinediones, was
introduced in 1997 and includes antidiabetic medications
such as troglitazone, pioglitazone, and rosiglitazone, the
chemical structure and mechanism of action of which are
very different from those of the other groups. Chemically,
they are thiazolidinediones having chroman moieties;
some of the analogues may present an aminoalkyl groupCardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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as a linker between the chroman ring and the phenoxy
moiety. Troglitazone, which was the first agent in this
class to receive labeling approval, was withdrawn from
clinical use in the US due to hepatotoxicity [30].
These drugs are insulin sensitizers, and they bind to the
PPAR gamma, leading to increased glucose transporter
expression. Sensitivity to insulin – especially in adi-
pocytes, muscle and liver – is improved, and an additional
major effect is the inhibition of hepatic gluconeogenesis
[31]. It should be pointed out that no increment in insulin
secretion is documented. PPARs are transcription factors
belonging to the superfamily of nuclear receptors; three
isoforms (alpha, beta/delta, gamma) are known nowa-
days, which regulate glucose homeostasis, lipoprotein
metabolism, local immune responses, local inflamma-
tion, tumors development, thrombosis and present also
potential antiatherogenic effects [32].
Rosilitazone monotherapy is only modestly effective in
reducing glucose and HgA1c levels. Plasma triglycerides
are reduced by 10–20%, and high density lipoprotein
(HDL) cholesterol levels increase by 5–10%, since it also
stimulates the isoform PPAR-alpha that regulates lipid
metabolism. These favorable effects are counterbalanced
by a 10–15% increase in low density lipoprotein (LDL)
cholesterol [33]. Edema has been reported in 5% of
patients, and glitazones are contraindicated in NYHA class
III or IV [33]. Regarding hepatotoxicity, studies with ros-
iglitazone and pioglitazone indicate that it is not a class
effect. Further differences in the safety profiles of these
agents arise because the oxidative metabolism for each
agent occurs by distinct cytochrome pathways: pioglita-
zone involves CYP 3A4 and CYP 2C8 whereas rosiglita-
zone is principally metabolized by CYP 2C8. CYP 3A4 is
involved in the metabolism of over 150 drugs, hence the
potential for drug interactions with pioglitazone is much
greater than with rosiglitazone. Class effects include slight
reductions in hemoglobin and hematocrit, due to
hemodilution [30].
It was stressed that rosiglitazone reduces urinary albumin
excretion in T2DM and may even mildly reduce blood
pressure [34]. Nontraditional markers of cardiovascular
disease – such as matrix metalloproteinase-9 – may be
reduced as well [35]. Another notorious characteristic of
glitazones is their capability of lowering leptin levels,
leading to several degrees of weight gain, usually propor-
tional to the administered dose [34]. This feature has
obvious harmful clinical implications and was docu-
mented in both experimental [36,37] and human studies
[34]. In addition, it was suggested that rosiglitazone may
be associated with a significant increase in the risk of myo-
cardial infarction and with an increase in the risk of death
from cardiovascular causes that had borderline signifi-
cance [38]. Since the publication of this meta-analysis, it
has been debated whether rosiglitazone should remain on
the market. To date, the US Food and Drug Administra-
tion (FDA) has concluded that there is insufficient evi-
dence to withdraw rosiglitazone, yet questions about its
cardiotoxicity persist. Most recently published studies in
this issue demonstrated that rosiglitazone may be safer
than previously thought: rosiglitazone does not increase
the risk of overall cardiovascular morbidity or mortality
compared with standard glucose-lowering drugs [39]. In
addition, when added to metformin or a sulfonylurea, a
12-month treatment with rosiglitazone reduced ambula-
tory blood pressure to a greater extent than when met-
formin and a sulfonylurea are combined [40], confirming
previous data regarding beneficial influence on blood
pressure [34].
Pioglitazone treatment in patients with advanced T2DM
at high risk for cardiovascular events participating in the
PROactive Study, yielded significant risk reductions in
major adverse events composite end points at 3 years
[41,42]. The risk of heart failure is a class effect of the thi-
azolidinediones, whereas the ischemic cardiovascular risk
is confined to rosiglitazone but not to pioglitazone. It
seems that the differential effects of rosiglitazone and
pioglitazone on metabolism may motivate the apparent
disparity in their impact on outcomes: for example, piogl-
itazone lowers LDL cholesterol while rosiglitazone raises
it [43].
Thus, glitazones exhibit a broad landscape of complex
clinical effects, in part favorable and in part detrimental
for the cardiovascular system. The concluding balance
between these effects requires further elucidation. In this
context, it should be mentioned that only few head-to-
head comparisons of drug regimens containing glitazones
versus drug regimens containing insulin were found [44].
This leaves clinicians unable to evaluate the effectiveness
of one combination regimen over another. Many pub-
lished large trials were composed by industry sponsored
studies, increasing so the concern that funding source
could influence outcomes and conclusions of the research
[44].
Alpha-glucosidase inhibitors
The primary mechanism of action of antidiabetic drugs
like acarbose, voglibose and miglitol is grounded on com-
petitive inhibition of several enzymes of the alpha-glu-
cosidase group (maltase, isomaltase, sucrase,
glucoamylase). These are membrane-bound enzymes that
hydrolyze oligosaccharides and disaccharides to glucose
in the brush border of the small intestine Thus, by delay-
ing digestion of carbohydrates, these compounds shift
their absorption to more distal parts of the small intestine
and colon, and defer gastrointestinal absorption of glu-Cardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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cose. Their hypoglycemic potency is less than that of
biguanides and sulfonylureas [33] and, unlike the latter,
they do not cause hypoglycemia. The most frequent side-
effects to these drugs are mild abdominal pain, flatulence
and diarrhea [45].
It is well established that impaired fasting glucose concen-
trations in nondiabetic patients with ischemic heart dis-
ease are a marker for a worse prognosis [46,47]. Acarbose
could be used, either as an alternative or in addition to
changes in lifestyle, to delay development of T2DM in
these patients. Acarbose is by far the most extensively
studied alpha-glucosidase inhibitor. The STOP-NIDDM
trial [45] is the largest randomized trial to date investigat-
ing the drug in subjects with prediabetes and early diabe-
tes. This study suggests that acarbose treatment was
associated with a reduction in hypertension and cardio-
vascular disease: this treatment resulted in a 25% relative
risk reduction in the development of T2DM, in a 34% risk
reduction in the development of new cases of hyperten-
sion, and in a 49% risk reduction in cardiovascular events.
Interestingly, and additional metabolic pathway for these
compounds was recently described. Chronic treatment
with voglibose stimulates GLP-1 secretion and decreases
plasma DPP-4 activity by reducing its circulating levels
[48,49]. Similar features were documented for miglitol
[50]. Thus, the antihyperglycemic effect of alpha-glucosi-
dase inhibitors is likely achieved by two parallel mecha-
nisms which are both direct and indirect. It directly
reversibly inhibits the α-glucosidase enzymes, and sec-
ondly, induces GLP-1 secretion.
Combined treatment with classical drugs
Combined therapy is based on the premise that pharma-
cological agents acting via different mechanisms and pre-
senting differing side effects permit the design of
individualized antidiabetic regimens. This approach
reflects the plausibility that monotherapy with any cur-
rently available medication is likely to fail over time in
some patients, and this type of pharmacological diabetes
management is widely used. Findings from the United
Kingdom Prospective Diabetes Study (UKPDS) showed
that after 3 years, approximately 50% of patients could
attain satisfactory glucose levels with monotherapy; by 9
years this had declined to only 25% [51]. Long-term prob-
lem-oriented prospective studies that focus specifically on
the outcome of coronary diabetics on combined therapy
are lacking. Data from an observational study – which
included exclusively documented coronary patients – per-
formed at our laboratory [52] indicated an all-cause
increased crude mortality over a mean 7.7-year follow-up
in diabetics on combined treatment with metformin and
glibenclamide. Figures on mortality in this group almost
quadrupled those of nondiabetic CAD patients (Figure 1).
These results were corroborated when multivariate analy-
sis was performed (Figure 2). Another study that focused
on the general diabetic population found that there was
an higher cardiovascular mortality in T2DM taking sulfo-
nylurea and metformin in combination than in those tak-
ing only sulfonylurea [53], concluding that it cannot be
excluded that this kind of combination therapy possibly
increases cardiovascular mortality. Combination therapy
is known to promote additional blood glucose reduction
but there is as yet no evidence that these or another antid-
iabetic formulations are beneficial in preventing or delay-
ing macrovascular disease. These observations are in
keeping with the UKPDS reports demonstrating excess
risk of all-cause mortality in the whole diabetic popula-
tion receiving combined therapy, especially in patients in
whom metformin was added at an early stage [54]. Like-
wise, a recent meta-analysis of observational studies [55]
further confirms that the combination therapy of met-
formin and sulfonylurea significantly increases the rela-
tive risk of the composite end point of cardiovascular
hospitalization or mortality (fatal and nonfatal events)
irrespective of the reference group – diet therapy or met-
formin or sulfonylurea monotherapies.
Hence, the combined antihyperglycemic treatment with
classical drugs leads to a peculiar entanglement since sul-
Histographical display of crude all-cause mortality (percent)  over a mean 7.7-year follow-up in 11,322 CAD patients –  nondiabetic and diabetic – on several therapeutic regimens Figure 1
Histographical display of crude all-cause mortality 
(percent) over a mean 7.7-year follow-up in 11,322 
CAD patients – nondiabetic and diabetic – on several 
therapeutic regimens. Mortality in patients on a com-
bined glibenclamide/metformin regimen was significantly 
higher and almost quadrupled the figures documented for 
nondiabetic CAD patients. Significant statistical differences 
were still present when comparing the group on combined 
pharmacotherapy with the groups on other antidiabetic 
regimes. ND – nondiabetics; diet – patients solely on diet; 
gliben – patients on glibenclamide; metfor – patients on met-
formin; comb – patients on a combined glibenclamide/met-
formin regimen. (Based on data from Ref. [45]).Cardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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fonylureas and metformin are 1) the most powerful anti-
abetic drugs; 2) those presenting the most unfavorable
cardiac effects; 3) the most frequently employed combina-
tion in routine clinical practice [56,57].
New compounds
Taking into consideration the intimate interrelationship
between diabetes and heart disease, the American Heart
Association has coined in 1999 the phrase 'diabetes is a
cardiovascular disease' [58]. Diabetic patients with CAD
connote an enormous population which deserve a specific
approach. Incretins, DPP-4 inhibitors, glitazars and the
amylin mimetic drugs represent novel pharmacological
approaches.
Incretins
The progressive impairment of beta cell function and
increased insulin demand as tissue becomes insulin resist-
ant are core pathophysiologic defects in the development
of hyperglycemia in T2DM [59,60]. Anyway, the process is
a complex one and other important factors are also
involved, further exacerbating the clinical setting. Excess
glucagon secretion, abnormally accelerated gastric empty-
ing during hyperglycemia, obesity, and increased food
intake all contribute to hyperglycemia. Impaired release
or action of incretin hormones, particularly GLP-1, and to
a lesser degree glucose-dependent insulinotropic polypep-
tide (GIP), also play a role in the development and/or
progression of T2DM. More recently, the essentially gluco-
centric view of the genesis and progression of T2DM has
been supplemented by a more lipocentric perspective.
Here the major mechanism is progressive ectopic lipid
deposition (e.g., in myocytes and hepatocytes, rather than
in adipocytes). Build-up of ectopic fat in those tissues ulti-
mately induces insulin resistance, cell lipotoxicity, and
diminished cell function, leading to metabolically inade-
quate insulin secretion [61].
Thus, incretin mimetic drugs are nowadays extensively
investigated. A key role for intestinal peptides in the regu-
lation of postprandial insulin secretion and glucose levels
was proposed, based on the observation that insulin
responses to an oral glucose load exceeded those meas-
ured after intravenous administration of an equivalent
amount of glucose [62]. This phenomenon, termed the
"incretin effect," postulated the existence of gut-derived
signals promoting insulin secretion in response to nutri-
ent intake [63]. Subsequently, the incretin hormones GIP
and GLP-1, were discovered [64]. These two principal
incretin hormones are small peptides – 42 and 30 amino
acids, respectively, that rapidly stimulate the release of
insulin only when blood glucose levels are elevated,
thereby enhancing the glucose-sensing and insulin secre-
tory capacity of the endocrine pancreas during postpran-
dial hyperglycemia [65].
Physiological actions of incretins were extensively defined
in animal studies with exogenous GLP-1 and GLP-1 recep-
tor antagonists, highlighting its role as a meal-stimulated
factor with potent glucose-lowering activity. Of significant
clinical relevance is that exogenous GLP-1 has the poten-
tial to normalize fasting plasma glucose concentrations in
patients with T2DM. In several studies in subjects with
diabetes, GLP-1- whether administered by intravenous or
subcutaneous infusion – normalized both fasting and
postprandial glycemia by enhancing glucose-mediated
insulin secretion, as well as by suppressing glucagon secre-
tion [66-69].
Additional studies in animals and humans have demon-
strated glucose-lowering effects of GLP-1. GLP-1 slows
gastric emptying to decrease the rate of nutrient absorp-
tion, which results in more synchronous nutrient delivery
with endogenous insulin action. Significant acute reduc-
tions in appetite and food intake after intravenous admin-
istration of GLP-1 in both healthy individuals and in
patients with T2DM have also been demonstrated [70-
72].
The mechanism through which the incretin hormones
elicit their cytoprotective effects on the beta cell has
attracted significant attention because preservation and
restoration of beta-cell mass may contribute to the thera-
peutic potential of the incretins for the treatment of both
Actuarial survival curves of all-cause mortality after multivar- iate analysis in the same population as in Figure 1 Figure 2
Actuarial survival curves of all-cause mortality after 
multivariate analysis in the same population as in Fig-
ure 1. Multivariate analysis included age, gender, glucose, 
cholesterol, triglycerides, previous myocardial infarction, 
anginal syndrome, hypertension, functional class, previous 
cerebrovascular accident, peripheral vascular disease, smok-
ing, body mass index and use of beta blockers and antiplatelet 
drugs. With patients on diet as reference group, the com-
bined treatment with metformin and glibenclamide was asso-
ciated with a significantly higher hazard ratio of all cause 
mortality: 1.53 (95% CI 120–1.96. (Modified from Ref. [45]).Cardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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type 1 and T2DM. Endoplasmic reticulum stress within
the beta cell, possibly occurring as the result of the over-
production or misfolding of insulin, may be a contribut-
ing factor to the increased beta-cell apoptosis and loss of
islet mass observed in diabetic patients [73].
Exenatide was first in the new class of incretin mimetics
for the treatment of patients with T2DM. Several short-
term phase 2 clinical trials have reported that subcutaneos
exenatide acutely lowered both fasting and postprandial
plasma glucose concentrations. The rate of gastric empty-
ing was also slowed in patients treated with exenatide.
Large-scale clinical trials designed to assess the safety and
efficacy of twice daily subcutaneos exenatide over a six-
month period were completed in subjects with T2DM
who were unable to attain glycemic control with oral sul-
fonylureas, metformin, or both [74]. A novel formulation
of exenatide consisting of biodegradable polymeric
microspheres that entrap exenatide and provide extended
release enabling once-weekly administration was recently
developed [75]. It resulted in significantly greater
improvements in glycemic control than exenatide given
twice a day, with no increased risk of hypoglycemia and
similar reductions in bodyweight [76].
Another incretin mimetic compound, liraglutide, is a
once-daily GLP-1 derivative in development for the treat-
ment of T2DM. GLP-1, in its natural form, is short-lived in
the body (the half-life after subcutaneous injection is
approximately 1 hour), so it is not very useful per se as a
therapeutic agent. However, prolonged activity is
achieved by chemical manipulation, reaching to 11–15
hours and making it suitable for once-daily dosing. This is
attained by attaching a fatty acid molecule at one position
of the GLP-1 molecule, enabling it to bind to albumin
within the subcutaneous tissue and bloodstream. The
active GLP-1 is then released from albumin at a slow, con-
sistent rate. Binding with albumin also results in slower
degradation and reduced elimination of liraglutide from
the circulation by the kidneys compared to its natural
form [77,78]. A recent report demonstrated that liraglu-
tide once a day provided significantly greater improve-
ments in glycemic control than did exenatide twice a day,
and was generally better tolerated. The results suggest that
liraglutide might be a treatment option for T2DM, espe-
cially when weight loss and risk of hypoglycemia are
major considerations [79].
Additional long-acting incretin mimetic drugs, like albi-
glutide and taspoglutide are currently under investigation,
presenting encouraging results [80,81].
Dipeptidyl peptidase-4 inhibitors
While discovered in 1967, serine protease DPP-4 was only
subject of intensive research during recent years. DPP-IV is
ubiquitously expressed and exhibits postproline or
alanine peptidase activity, thereby generating biologically
inactive peptides via cleavage at the N-terminal region
after X-proline or X-alanine. It is a complex molecule that
exists as a membrane-spanning cell-anchored protein that
is expressed on many cell types, and as a soluble form in
the circulation; both forms have proteolytic activity.
Because both GLP-1 and GIP have an alanine residue at
position 2, they are substrates for DPP-4. DPP-4 inhibitors
like sitagliptin are orally administered drugs that improve
glycemic control by preventing the rapid degradation of
incretin hormones, thereby resulting in postprandial
increases in levels of biologically active intact GLP-1 and
GIP [82,83].
Sitagliptin is an orally-bioavailable selective DPP-4 inhib-
itor – the first one approved by the FDA – that was discov-
ered through the optimization of a class of beta-
aminoacid-derived DPP-4 inhibitors. It lowers DPP-4
activity in a sustained manner following once daily
administration, preserves the circulating levels of intact
GIP and GLP1 following meals in both acute and chronic
studies and reduces blood glucose levels without signifi-
cant increases in hypoglycemia [84]. Thus, the drug works
by inhibiting the inactivation of the incretin GLP-1 and
GIP by DPP-4. By preventing GLP-1 and GIP inactivation,
GLP-1 and GIP are able to potentiate the secretion of insu-
lin and suppress the release of glucagon by the pancreas.
As the blood glucose level approaches normal, the
amounts of insulin released and glucagon suppressed
diminishes thus tending to prevent an overshoot and sub-
sequent hypoglycemia which is seen with some other oral
hypoglycemic agents.
Several additional DPP4 inhibitors, like saxagliptin, vild-
agliptin and alogliptin are currently investigated. Vild-
agliptin is the second DPP-4 inhibitor approved in
Europe. Similarly to sitagliptin, vildagliptin has pharma-
cokinetic properties that support a once daily dosing regi-
men. Alogliptin in combination with pioglitazone, in an
experimental model, improves glycemic control, lipid
profiles, and increases pancreatic insulin content [85].
Whereas hepatic insufficiency does not seem to alter phar-
macokinetics of these compounds, dose adjustments are
required in patients with renal impairment, at least for sit-
agliptin [86]. Their beneficial effects are 1. increase circu-
lating levels of GLP-1 in animals and humans; 2. increase
the genesis, proliferation and differentiation of beta cells;
3. inhibit apoptosis of these cells; 4. enhance insulin
secretion; 5. reduce fasting glucose; 6. reduce postparan-
dial glucose; 7. reduce HbA1c levels.
In comparison to DPP-4 inhibitors, incretin mimetic
agents have more pharmacological specificity but require
subcutaneous injections. As with DPP-4 inhibitors,
improvements in glycemic control were achieved withCardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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either no weight gain or with weight loss. Considering the
impact of obesity on diabetes, along with weight gain that
generally accompanies the use of insulin, insulin secreta-
gogues, and insulin sensitizers, interventions with favora-
ble effects on weight are likely to become increasingly
important.
It should be pinpointed that there is a risk of potential
adverse effects of DPP-4 inhibitors, especially on the
immune system: an increased relative risk of 34% for all-
cause infections after sitagliptin treatment was observed.
Although, the risk of increased infection appears small, its
consequences when translated into clinical practice with
millions of T2DM patients treated could be considerable
[87]. Thus, while DPP-4 inhibitors present some advan-
tages over other antidiabetic agents, long-term data on
potential cardiovascular effects are needed before wide-
spread use of these drugs is recommended.
Dual and pan-PPAR agonists
There are three PPARs subtypes which are commonly des-
ignated PPAR alpha, PPAR gamma and PPAR beta/delta.
PPAR alpha activation increases HDL cholesterol synthe-
sis, stimulates "reverse" cholesterol transport and reduces
triglycerides. PPAR gamma activation results in insulin
sensitization and antidiabetic action. Until recently, the
biological role of PPAR beta/delta remained unclear.
However, treatment of obese animals by specific PPAR
delta agonists results in normalization of metabolic
parameters and reduction of adiposity. Combined treat-
ments with PPAR gamma and alpha agonists may poten-
tially improve insulin resistance and alleviate atherogenic
dyslipidemia, whereas PPAR delta properties may prevent
the development of overweight which typically accompa-
nies "pure" PPAR gamma ligands. Clearly, an optimal
PPAR agent with improved safety profile that provides
both effective glycemic and lipid control is needed. Com-
pounds that affect both PPAR-alpha and PPAR-gamma,
particularly with an optimized balance of agonist activity,
might prove especially beneficial for patients with T2DM
[88].
The old and well known lipid-lowering fibric acid deriva-
tive bezafibrate is the first clinically tested pan-(alpha,
beta/delta, gamma) PPAR activator. It is the only pan-
PPAR activator with more than a quarter of a century of
therapeutic experience with a good safety profile. There-
fore, bezafibrate could be considered (indeed, as a "post
hoc" understanding) as an "archetype" of a clinically
tested pan-PPAR ligand. Bezafibrate leads to considerable
raising of HDL cholesterol and reduces triglycerides,
improves insulin sensitivity and reduces blood glucose
level, significantly lowering the incidence of cardiovascu-
lar events and new diabetes in patients with features of the
metabolic syndrome. It attenuates the progression of insu-
lin resistance, defers the onset of overt T2DM, enhances
adiponectin levels and reduces the incidence of myocar-
dial infarction in patients with metabolic syndrome dur-
ing long-term follow-up [89-95]. However, from a
biochemical point of view, bezafibrate is a PPAR ligand
with a relatively low potency.
Several novel and potent dual PPAR-alpha/gamma ago-
nists (glitazars) have been clinically developed. These
agents have a major effect on peripheral and hepatic insu-
lin sensitivity, with HbA1c reductions of 0.5–2%. On the
basis of their mode of action, it is expected that these
agents could modulate cardiovascular risk by improving
endothelial reactivity, reducing blood pressure, and
improving lipid profiles [96]. However, the emergence of
different types of toxic effects in clinical trials has resulted
in their failure to progress beyond phase III development.
Nonetheless, no consistent safety signal has been
detected, probably because PPAR-alpha and PPAR-
gamma each control the expression of many proteins that
are involved in a range of biological processes. For exam-
ple, development of tesaglitazar was discontinued
because of indications that it could cause renal impair-
ment, muraglitazar was linked with cardiovascular safety
issues, and the earlier agents ragaglitazar and farglitazar
failed because of liver toxicity and tumors in rodents.
The recently reported SYNCHRONY study [97] aimed to
establish the safety profile and glucose-lowering and
lipid-modifying effects of the new compound aleglitazar
[98]. Aleglitazar significantly reduced baseline HbA1c ver-
sus placebo in a dose-dependent manner, with a 600 μg
dose. Edema, hemodilution, and weight gain occurred
and were dose-dependent. However, at aleglitazar doses
less than 300 μg, no patients had congestive heart failure,
frequency of edema was similar to placebo and less than
with pioglitazone, and bodyweight gain was less than
with pioglitazone. The favorable balance in the safety and
efficacy profile of aleglitazar represents encouraging short-
term clinical data for this agent and provides good evi-
dence to enter phase III investigation. Thus, the future of
these dual PPAR agonists is presently uncertain following
former concerns about their safety. However, the favora-
ble changes in lipids and glycemic endpoints still encour-
age further research.
Amylin mimetic drugs
Amylin is a synergistic partner to insulin, with which it is
cosecreted from pancreatic beta cells in response to meals.
Deficient amylin secretion is a well-recognized phenome-
non in type 1 diabetes and in a later-stage in T2DM, in
whom pancreatic insulin production is markedly reduced.
Its physiological effects mimic in part those of GLP-1.
Amylin suppresses glucagon – a pancreatic hormone that
regulates the production of glucose by the liver – secretionCardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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from pancreatic alpha cells, thereby attenuating hepatic
glucose production. It also delays gastric emptying and
likely possesses a central effect to enhance satiety [99].
Pramlintide is a synthetic hormone for parenteral (subcu-
taneous) administration, resembling human amylin
effects. It reduces the production of glucose by the liver by
inhibiting the action of glucagon and diminishes post-
prandial glucose fluctuations. The drug was approved by
the FDA in March 2005. While it seems to be a satisfactory
adjuvant medication in insulin-dependent diabetes, it is
unlikely to play a major future role in the management of
T2DM [100].
Cardiovascular effects of the new compounds
While he main physiologic benefits demonstrated from
exenatide therapy have been on indexes of glycemic con-
trol, cardiovascular effects have also been described. In
experimental models, GLP-1 receptors have been demon-
strated in cardiac myocytes and in certain regions of the
brain that regulate autonomic function [101]. In some
cases the use of GLP-1 infusion was associated with a dou-
bling of stroke volume and an increase in cardiac output
by > 50%, as well as significant decreases in left ventricular
end-diastolic volume [102]. Encouraging results were also
documented in humans [103], but long-term safety data
are required before we fully understand any potential ben-
efits or risks derived from the hemodynamic influences of
GLP-1-based therapies.
Regarding DPP-4 inhibitors, few data are available con-
cerning cardiovascular markers or clinical outcomes.
Given the preliminary data they might be considered in
individuals with impaired ventricular function. However,
no clinical trials using these agents have yet been reported
in this or any other group of patients with cardiovascular
disease. Glitazars may yield some reduction in blood pres-
sure [96]. The amylin mimetic drug pramlintide did not
show cardiovascular advantages or risks [99].
Clinical implications
Our pharmacological armamentarium is nowadays
increasingly complex, offering a wide array of drugs, both
as monotherapy or in combination. It is therefore fre-
quently difficult to determine the best therapeutic option
for a given patient. A common problem arises when a
drug is known to give a prompt and beneficial effect in the
short term, but data regarding long-term outcome and
safety are either lacking or insufficient. This is particularly
true regarding antihyperglycemic drugs in patients with
CAD.
Comprehensive risk reduction is mandatory for diabetic
patients with CAD. General measures should comprise
diet, physical activity, complete cessation of smoking, and
weight and lipid profile management. However, fewer
than 10% of patients achieve acceptable long-term glyc-
emic values with non-pharmacological therapy only
[104]. Special emphasis should be given to blood pressure
control; we have reported the presence of widespread
undiagnosed hypertension in this population, which pre-
sented a 5-year mortality even higher than that in diabet-
ics previously identified as hypertensives [105]. Moreover,
the increased mortality associated with hypertension in
mild diet-treated type 2 diabetes strongly supports the
need for early onset of antihypertensive treatment in these
patients [106]. When examining the status of glucose
metabolism in patients with heart failure secondary to
CAD, it is disclosed that both T2DM and impaired fasting
glucose are associated with increased prevalence of heart
failure among patients with CAD [107].
Evidence is available that long-term maintenance of nor-
mal or near-normal glucose levels using pharmacological
means is protective in diabetic patients, improving micro-
vascular disease (retinopathy, nephropathy, and neuropa-
thy) and reducing both morbidity and mortality
[108,109]. Is this also applicable to coronary diabetics?
Current data indicate that the answer is positive, but alle-
viation of macrovascular complications remains dubious.
Moreover, the therapeutic criteria for T2DM patients with-
out proven heart disease should not be automatically
extrapolated to cardiac diabetic patients, who need a care-
fully customized treatment. The pathogenesis of athero-
sclerosis spans decades. Thus, there is an emerging notion
that tight glycemic control may be beneficial in primary
prevention of cardiovascular disease in younger patients
with T2DM, but may become deleterious in older patients
with established disease. Then, while a tight glycemic con-
trol may lessen microvascular disease, it may increase the
risk for adverse cardiovascular events [110].
What should the policy be regarding the widely used sul-
fonylurea-metformin combined treatment? Following
approval of a given therapy for a chronic condition, large
prospective, randomized, placebo-controlled trials
designed to check its long-term safety and effectiveness
require many years to be completed, and sometimes such
studies are not performed at all. This is the case with this
combined treatment in CAD patients. The data from
observational studies available at present indicate
increased mortality in patients receiving this therapy [52-
55] suggesting that this combination should be used with
caution in diabetics with proven CAD. The excessive mor-
tality rate could reflect an additive expression of the
adverse cardiovascular effects of each of these medica-
tions. However, we would like to stress that our own
observations specifically address the glibenclamide-met-
formin combined treatment [52] and we have no infor-
mation regarding combinations of metformin with other
sulfonylureas, such as glimepiride or gliclazide.Cardiovascular Diabetology 2009, 8:38 http://www.cardiab.com/content/8/1/38
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Conclusion
Based on current data, stringent guidelines or strategies
regarding non-insulin antidiabetic pharmacotherapy in
T2DM patients with heart disease cannot yet be outlined.
Anyhow, summarizing the available information it can be
stated that
1. Four out the five classical oral antidiabetic drug groups
present proven or potential cardiac hazards.
2. These hazards are not mere 'side effects', but biochemi-
cal phenomena which are deeply rooted in the drugs'
mechanism of action.
3. Current data indicate that the combined glibencla-
mide/metformin therapy seems to present special risk and
should be avoided in the long-term management of type
2 diabetics with proven CAD.
4. Glitazones should be avoided in patients with overt
heart failure.
5, The novel incretin mimetic drugs and DPP-4 inhibitors
– while usually relatively ineffective as monotherapy –
appear to be satisfactory adjuvant drugs due to the lack of
known undesirable cardiovascular effects.
6. Customized antihyperglycemic pharmacological
approaches should be implemented for the achievement
of optimal treatment of T2DM with heart disease. In this
context, it should be carefully taken into consideration
whether the leading clinical status is CAD or heart failure.
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